Jaguar Health Q1 revenue up 816% to $20.3M on $19M license deal; net loss narrows to $7.0M

Jaguar Health, Inc.

2026-Q1 EPS reported -$13.60 vs consensus -$2.08 ▼ miss (-553.6%)

Total revenue $20.3M (816% YoY increase) driven by $19.1M license revenue from Woodward/Future Pak deal.
Product revenue $1.2M, down 45% YoY; Mytesi/Canalevia-CA1 rights licensed to Future Pak in Jan 2026.
Net loss attributable to common stockholders $7.0M, improved 33% from $10.5M loss in Q1 2025.
Non-GAAP recurring EBITDA loss $5.1M, improved 48% from $9.7M loss a year ago.
Company to present crofelemer data for rare-disease intestinal failure at ESPGHAN June 2026.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.